Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAPLEX dose comparison for major bleeding on factor Xa inhibitor DOAC therapy
2021-000740-21Phase 3Active
- Sponsor
- Octapharma
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of coagulation factor X human in Not applicable and coagulation defects (2 arms), sponsored by Octapharma. Primary endpoint: Haemostatic effectiveness. Started Oct 2021; status: active.
02
Drugs
coagulation factor X human
03
Conditions
Not applicablecoagulation defects
Beyond the preview
Go deeper on 2021-000740-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000740-21.